Medline ® Abstract for Reference 142
of 'Treatment of relapsed or refractory chronic lymphocytic leukemia'
Alemtuzumab in combination with high-dose methylprednisolone is a logical, feasible and highly active therapeutic regimen in chronic lymphocytic leukaemia patients with p53 defects.
Pettitt AR, Matutes E, Oscier D
Leukemia. 2006;20(8):1441. Epub 2006 Jun 1.